An antibody-lectin sandwich assay for the determination of CA125 antigen in ovarian cancer patients.
A two-step forward sandwich assay was developed for the determination of the ovarian tumour associated glycoconjugate antigen CA125 with anti-CA125 Monoclonal antibody B27.1 on the solid phase and 125I-labelled wheat germ lectin as tracer in the solution phase. This Mab-lectin heterosandwich assay was optimized and the clinical utility was evaluated in sera from healthy volunteers and ovarian cancer patients. A correlation was established between Mab-lectin assay and the dual monoclonal antibody sandwich assay, TRUQUANTOV2 RIA, that uses the same MAb B27.1 on the solid phase and a second 125I-labelled B43.13 MAb in the solution phase. A potentially improved clinical utility is suggested for the Mab-lectin assay. The unique format seems to identify novel isoforms of CA125 with different carbohydrate side chains that would otherwise be undetectable in the MAb-MAb sandwich assay wherein the paratopes are likely directed to protein determinants.
Madiyalakan
R
R
Biomira Research Inc., Edmonton, Alberta, Canada.
Kuzma
M
M
Noujaim
A A
AA
Suresh
M R
MR
D000906:Antibodies / Q000276:immunology*; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000937:Antigen-Antibody Reactions; D018394:CA-125 Antigen / Q000097:blood*; D005260:Female; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D037102:Lectins / Q000276:immunology*; D010051:Ovarian Neoplasms / Q000276:immunology*
D000906:Antibodies; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018394:CA-125 Antigen; D037102:Lectins; C107428:oregovomab